• Explore /
  • Poster
  • / Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).

Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).

Abstract Poster

Authors

null

James J. Harding

Memorial Sloan-Kettering Cancer Center, New York, NY

James J. Harding , Federica Catalanotti , Amin Yaqubie , Gregory C. McDermott , Romona Kersellius , Taha Merghoub , Richard D. Carvajal , Sandra P. D'Angelo , Mark Andrew Dickson , Gary K. Schwartz , Jedd D. Wolchok , Michael F. Berger , David B. Solit , Paul B. Chapman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Citation

J Clin Oncol 31, 2013 (suppl; abstr 9060)

DOI

10.1200/jco.2013.31.15_suppl.9060

Abstract #

9060

Poster Bd #

46G

Abstract Disclosures

Similar Posters

First Author: Melissa K. Yee

First Author: Jose A. Lopez-Martin

First Author: Clara Allayous

First Author: Zeynep Eroglu